Analysis of the delta F508 mutation in a Brazilian cystic fibrosis population: comparison of pulmonary status of homozygotes with other patients.
Sixty-one cystic fibrosis patients admitted for check-up or antibiotic treatment were enrolled for genetic and clinical evaluation. Genetic analysis was performed on blood samples stored on neonatal screening cards using PCR techniques to determine the presence of delta F508 mutations. Clinical evaluation included Shwachman and Chrispin-Norman scores, age at onset of symptoms and diagnosis, spirometry, awake and sleep pulse oximetry, hyponychial angle measurement and presence of chronic Pseudomonas aeruginosa colonization. Eighteen patients (29.5%) were homozygous for the delta F508 mutation, 26 (42.6%) had one delta F508 mutation and 17 (27.9%) were noncarriers, corresponding to a 50.8% prevalence of the mutation in the whole population. Analysis by the Kruskal-Wallis test for comparison of genetic status with continuous variables or by the chi-square test and logistic regression for dichotomous variables showed no significant differences between any two groups for alpha = 0.05. We conclude that genetic status in relation to the delta F508 mutation is not associated with pulmonary status as evaluated by the above variables.
Maróstica
P J
PJ
Unidade de Pneumologia Pediátrica, Hospital de Clínicas de Porto Alegre, RS, Brasil. pmarostica@nutecnet.com.br
Raskin
S
S
Abreu-e-Silva
F A
FA
D000293:Adolescent; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D006720:Homozygote; D006801:Humans; D007223:Infant; D016015:Logistic Models; D008168:Lung / Q000503:physiopathology*; D008297:Male; D009154:Mutation / Q000235:genetics*; D016017:Odds Ratio; D010649:Phenylalanine / Q000235:genetics*; D012129:Respiratory Function Tests
D010649:Phenylalanine